EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)

Safety, Biodistribution, and Radiation Dosimetry of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors

Elisabeth von Guggenberg, Gianpaolo di Santo, Christian Uprimny, Steffen Bayerschmidt, Boris Warwitz, Anton A Hörmann, Taraneh S Zavvar, Christine Rangger, Clemens Decristoforo, Anna Sviridenko, Bernhard Nilica, Giulia Santo und 1 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268877 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Elisabeth von Guggenberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Gallium Radioisotopes, Gastrins, Neuroendocrine Tumors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the 68Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 (68Ga-DOTA-MGS5).

Methods

Six patients with advanced MTC and 6 patients with gastroenteropancreatic and bronchopulmonary NETs confirmed by previous PET/CT imaging with other PET tracers received a single dose of 180 MBq of 68Ga-DOTA-MGS5. The first 6 patients enrolled in the study were included in the dosimetry evaluation, and safety was assessed in all 12 patients. PET/CT imaging was performed at different time points after injection to perform dosimetric calculations and to determine the optimal imaging time window. In addition, blood and urine samples were collected for pharmacokinetic assessments.

Results

The administration of 68Ga-DOTA-MGS5 was well tolerated, with minor adverse drug reactions occurring only in 3 patients. 68Ga-DOTA-MGS5 was cleared rapidly from the blood, with less than 21% of the injected activity present in blood 215 ± 10 min after injection. Tracer elimination occurred mainly through the kidneys, with a cumulative urinary excretion greater than 40% 3 h after injection. A high percentage of intact radiopeptide was confirmed in plasma. The highest absorbed dose was found for the urinary bladder wall, the stomach wall, and the kidneys, with an effective dose of 0.023 ± 0.007 mSv/MBq. The time points of 1 and 2 h after injection proved to be optimal for PET/CT imaging. In the 6 patients included in the dosimetry evaluation, local metastasis was confirmed in 2 patients with advanced MTC, whereas only 1 of 4 patients with gastroenteropancreatic NETs was positive in 68Ga-DOTA-MGS5 PET/CT.

Conclusion

Besides confirming the safety of administration, within the phase I part of the prospective clinical trial, an acceptable effective whole-body dose, an overall favorable biodistribution, and the feasibility of cholecystokinin-2 receptor imaging could be shown for 68Ga-DOTA-MGS5.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineGallium RadioisotopesGastrinsNeuroendocrine TumorsThyroid NeoplasmsCoordination ComplexesAdultAgedFemaleHumansMaleMiddle AgedPilot ProjectsPositron Emission Tomography Computed TomographyRadiometryTissue Distribution

Stichwörter der Autor:innen

68GaPETcholecystokinin-2 receptormedullary thyroid cancerminigastrinneuroendocrine tumors

Substanzen

Gallium RadioisotopesGastrins68Ga-DOTA-minigastrinCoordination Complexes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria irene.virgolini@i-med.ac.at.

Zitieren

APA

von Guggenberg, E., di Santo, G., Uprimny, C., Bayerschmidt, S., Warwitz, B., Hörmann, A. A., Zavvar, T. S., Rangger, C., Decristoforo, C., Sviridenko, A., Nilica, B., Santo, G., & Virgolini, I. J. (2025). Safety, Biodistribution, and Radiation Dosimetry of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268877

Vancouver

von Guggenberg E, di Santo G, Uprimny C, Bayerschmidt S, Warwitz B, Hörmann AA, et al. Safety, Biodistribution, and Radiation Dosimetry of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268877

BibTeX
@article{vonGuggenberg2025,
  author = {von Guggenberg, Elisabeth and di Santo, Gianpaolo and Uprimny, Christian and Bayerschmidt, Steffen and Warwitz, Boris and Hörmann, Anton A and Zavvar, Taraneh S and Rangger, Christine and Decristoforo, Clemens and Sviridenko, Anna and Nilica, Bernhard and Santo, Giulia and Virgolini, Irene J},
  title = {Safety, Biodistribution, and Radiation Dosimetry of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268877}
}
Kostenlos starten →